Malihe Mohamadian1,2, Hossein Chiti3, Alireza Shoghli4, Sajjad Biglari5, Negin Parsamanesh3, Abdolreza Esmaeilzadeh6,7. 1. Department of Molecular Medicine, Birjand University of Medical Sciences, Birjand, Iran. 2. Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. 3. Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran. 4. Social Determinants of Health Research Center, Zanjan University of Medical Sciences, Zanjan, Iran. 5. School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. 6. Department of Immunology, Zanjan University of Medical Science, Zanjan, Iran. 7. Cancer Gene Therapy Research Center, Zanjan University of Medical Science, Zanjan, Iran.
Abstract
BACKGROUND: At the end of December 2019, a novel coronavirus tentatively named SARS-CoV-2 in Wuhan, a central city in China, was announced by the World Health Organization. SARS-CoV-2 is an RNA virus that has become a major public health concern after the outbreak of the Middle East Respiratory Syndrome-CoV (MERS-CoV) and Severe Acute Respiratory Syndrome-CoV (SARS-CoV) in 2002 and 2012, respectively. As of 29 October 2020, the total number of COVID-19 cases had reached over 44 million worldwide, with more than 1.17 million confirmed deaths. DISCUSSION: SARS-CoV-2 infected patients usually present with severe viral pneumonia. Similar to SARS-CoV, the virus enters respiratory tract cells via the angiotensin-converting enzyme receptor 2. The structural proteins play an essential role in budding the virus particles released from different host cells. To date, an approved vaccine or treatment option of a preventive character to avoid severe courses of COVID-19 is still not available. CONCLUSIONS: In the present study, we provide a brief review of the general biological features of CoVs and explain the pathogenesis, clinical symptoms and diagnostic approaches regarding monitoring future infectivity and prevent emerging COVID-19 infections.
BACKGROUND: At theend of December 2019, a novel coronavirus tentatively named SARS-CoV-2 in Wuhan, a central city in China, was announced by the World Health Organization. SARS-CoV-2 is an RNA virus that has become a major public health concern after the outbreak of theMiddle East Respiratory Syndrome-CoV (MERS-CoV) and Severe Acute Respiratory Syndrome-CoV (SARS-CoV) in 2002 and 2012, respectively. As of 29 October 2020, the total number of COVID-19 cases had reached over 44 million worldwide, with more than 1.17 million confirmed deaths. DISCUSSION: SARS-CoV-2 infectedpatients usually present with severe viral pneumonia. Similar to SARS-CoV, the virus enters respiratory tract cells via the angiotensin-converting enzyme receptor 2. The structural proteins play an essential role in budding the virus particles released from different host cells. To date, an approved vaccine or treatment option of a preventive character to avoid severe courses of COVID-19 is still not available. CONCLUSIONS: In the present study, we provide a brief review of the general biological features of CoVs and explain the pathogenesis, clinical symptoms and diagnostic approaches regarding monitoring future infectivity and prevent emerging COVID-19infections.
Authors: Adedoyin Oyeyimika Ogunyemi; Adedunni Wumi Olusanya; Adesina Paul Arikawe; Oluwarotimi Bolaji Olopade; Uyiekpen Ima-Edomwonyi; Roland Oluwapelumi Ojo Journal: Pan Afr Med J Date: 2022-06-01